Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-17

Clinical Trial Update: Eslicarbazepine Acetate Monotherapy Long Term Study [Phase 3]

View source ↗

Summary

A Phase 3 long-term monotherapy trial of eslicarbazepine acetate in epilepsy has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • APTIOM (Eslicarbazepine acetate)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2018-07-17